GRANULES: Strong Q1 growth, margin gains, and robust outlook driven by complex generics and innovation
Q1 FY 2027 saw 22% revenue growth, margin expansion, and strong cash flow, led by complex generics and peptide CDMO. Guidance remains positive for sustained growth and margins, with major launches and capacity ramp-ups planned.Based on Granules India Limited [GRANULES] Q1 26/27 Audio Transcript — J…